Acceleron expands Celgene collaboration

Acceleron Pharma Inc. and Celgene Corp. said today that they have entered into a joint development and commercialization agreement for a potential anemia treatment called ACE-536.

As part of the agreement, New Jersey-based Celgene will make an upfront payment of $25 million to Acceleron, which is headquartered in Cambridge. According to a press release issued by the companies, Acceleron is eligible to receive development, regulatory, and commercial milestones of up to $217 million for the ACE-536 program.

The companies said they already have a collaboration around another product that they entered into in 2008.